BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Takaya H, Namisaki T, Shimozato N, Kaji K, Kitade M, Moriya K, Sato S, Kawaratani H, Akahane T, Matsumoto M, Yoshiji H. ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma. World J Gastrointest Oncol 2019; 11(5): 424-435 [PMID: 31139312 DOI: 10.4251/wjgo.v11.i5.424]
URL: https://www.wjgnet.com/1948-5204/full/v11/i5/424.htm
Number Citing Articles
1
Binquan Wu, Amin Li, Yinci Zhang, Xueke Liu, Shuping Zhou, Huaiyong Gan, Shiyu Cai, Yong Liang, Xiaolong Tang. Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticlesExpert Opinion on Drug Delivery 2020; 17(4): 573 doi: 10.1080/17425247.2020.1730809
2
Nathalie Théret, Fidaa Bouezzeddine, Fida Azar, Mona Diab-Assaf, Vincent Legagneux. ADAM and ADAMTS Proteins, New Players in the Regulation of Hepatocellular Carcinoma MicroenvironmentCancers 2021; 13(7): 1563 doi: 10.3390/cancers13071563
3
Jiejun Hu, Dong Cai, Zhibo Zhao, Guo-Chao Zhong, Jianping Gong. Suppression of Heterogeneous Nuclear Ribonucleoprotein C Inhibit Hepatocellular Carcinoma Proliferation, Migration, and Invasion via Ras/MAPK Signaling PathwayFrontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.659676
4
Hiroaki Takaya, Tadashi Namisaki, Kei Moriya, Naotaka Shimozato, Kosuke Kaji, Hiroyuki Ogawa, Koji Ishida, Yuki Tsuji, Daisuke Kaya, Hirotestu Takagi, Yukihisa Fujinaga, Norihisa Nishimura, Yasuhiko Sawada, Hideto Kawaratani, Takemi Akahane, Masanori Matsumoto, Hitoshi Yoshiji. Association between ADAMTS13 activity–VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinomaWorld Journal of Gastroenterology 2020; 26(45): 7232-7241 doi: 10.3748/wjg.v26.i45.7232